Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
(2024, September) Retatrutide is a novel triple-agonist targeting GLP-1, GIP, and glucagon receptors, showing in phase 2 trials that it can deliver remarkably large weight losses (up to ~24% over 48 weeks in people with obesity) along with strong improvements in HbA1c, lipid profiles, liver fat (in NAFLD), insulin sensitivity, and other cardiometabolic markers
Phase I metabolism generates primary metabolites, which are often intermediate products with increased polarity compared to the parent compound
15% for semaglutide) but may cause more initial nausea
Pair with a protein rich breakfast
US$ 25.13
US$ 25.97
US$ 24.00
US$ 21.28
US$ 24.63
